TUESDAY, Aug. 24 (HealthDay News) -- Patients who have a heart
transplant to correct the most common type of genetic heart disease
-- hypertrophic cardiomyopathy -- have better long-term survival
rates than those who have transplants for other heart diseases, a
new study finds.
In patients with hypertrophic cardiomyopathy (HCM), the pumping
chamber of the heart, known as the left ventricle, thickens over
time. This makes it stiff and less able to relax in order for blood
to fill the heart chambers. This serious, potentially fatal
condition affects about 500,000 people in the United States.
In the new study, published online Aug. 24 in the journal
Circulation: Heart Failure, U.S. researchers analyzed data from 26,706 adult heart transplant patients included in the United Network of Organ Sharing Registry. HCM patients account for about 1 percent of all heart transplants performed nationwide.
One year after transplant, the survival rate was 85 percent for
patients in the hypertrophic cardiomyopathy group and 82 percent
for those with other heart diseases. The survival rates were 75
percent and 70 percent, respectively, after five years, and 61
percent and 49 percent, respectively, after 10 years.
"Patients with this disease who are undergoing transplant can expect reasonable long-term survival rates -- that's a crucial clinical message for this small but important subgroup of patients," lead author Dr. Martin S. Maron, an assistant professor of medicine, director of the Hypertrophic Cardiomyopathy Center and co-director of Advanced Cardiac Imaging at Tufts Medical Center in Boston, said in an American Heart Association news release.
The U.S. National Library of Medicine has more about